Table 3 Progression probabilities after 1 year, 3 years, and 5 years
From: Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project
Demographics only | CSF | |||||||
|---|---|---|---|---|---|---|---|---|
Age | Sex | MMSE | Normal | AB abnormal | Tau abnormal | Both abnormal | ||
1 year | 55 | m | 30 | 2% [0–2] | 0% [0–1] | 0% [0–2] | 12% [3–38] | 26% [7–71] |
27 | 3% [2–5] | 0% [0–2] | 0% [1–5] | 26% [8–65] | 51% [18–92] | |||
f | 30 | 2% [0–2] | 0% [0–1] | 0% [0–1] | 6% [2–23] | 15% [4–48] | ||
27 | 3% [2–5] | 0% [0–1] | 0% [1–3] | 15% [4–44] | 32% [9–77] | |||
70 | m | 30 | 5% [3–9] | 5% [2–15] | 13% [5–34] | 4% [1–11] | 8% [3–20] | |
27 | 11% [7–16] | 12% [5–30] | 29% [11–64] | 9% [3–21] | 19% [9–36] | |||
f | 30 | 5% [3–9] | 3% [1–9] | 7% [2–22] | 3% [1–6] | 5% [2–12] | ||
27 | 11% [7–16] | 7% [2–22] | 16% [5–46] | 5% [2–12] | 10% [4–24] | |||
3 years | 55 | m | 30 | 4% [2–8] | 0% [0–2] | 1% [1–6] | 32% [10–78] | 60% [20–98] |
27 | 9% [6–14] | 1% [0–5] | 2% [0–12] | 60% [23–95] | 89% [44–99] | |||
f | 30 | 4% [2–8] | 0% [0–1] | 1% [0–3] | 19% [5–55] | 39% [11–87] | ||
27 | 9% [6–14] | 0% [0–3] | 1% [0–7] | 39% [12–84] | 69% [26–99] | |||
70 | m | 30 | 15% [10–21] | 16% [6–39] | 35% [14–72] | 13% [4–27] | 23% [11–46] | |
27 | 28% [21–37] | 33% [14–71] | 64% [30–96] | 24% [10–49] | 48% [28–71] | |||
f | 30 | 15% [10–21] | 9% [3–25] | 21% [7–53] | 7% [3–16] | 16% [6–29] | ||
27 | 28% [21–37] | 21% [7–53] | 43% [15–85] | 14% [5–32] | 29% [14–50] | |||
5 years | 55 | m | 30 | 6% [3–11] | 1% [0–3] | 1% [0–8] | 43% [13–89] | 73% [27–98] |
27 | 12% [8–20] | 1% [1–7] | 4% [1–17] | 73% [30–99] | 96% [56–100] | |||
f | 30 | 6% [3–11] | 0% [0–2] | 1% [0–4] | 25% [7–69] | 51% [16–94] | ||
27 | 12% [8–20] | 1% [0–4] | 2% [0–10] | 50% [17–93] | 81% [35–98] | |||
70 | m | 30 | 20% [14–29] | 22% [9–51] | 47% [19–84] | 17% [6–36] | 32% [16–58] | |
27 | 38% [29–49] | 44% [19–83] | 78% [39–98] | 32% [24–62] | 60% [38–83] | |||
f | 30 | 20% [14–29] | 13% [4–34] | 28% [10–66] | 10% [5–22] | 21% [8–38] | ||
27 | 38% [29–49] | 28% [10–66] | 55% [20–94] | 20% [10–39] | 39% [20–66] | |||